Latest Unsolved problems in neuroscience Stories
Researchers at Universitat Autònoma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the ß-amyloid protein, involved in Alzheimer's disease.
5.4 million Americans suffer from Alzheimers and 3 million from Parkinson's disease. Doctors who treat patients with these among other neurodegenerative conditions believe that the diseases are spreading though their patients' brains. The stages of both Alzheimers and Parkinson's disease show these pathological effects.
Scientists from The Scripps Research Institute and Pfizer Inc. have published a new study showing how a new drug called tafamidis (Vyndaqel®) works.
Pathological aging (PA) is used to describe the brains of people which have Alzheimer's disease (AD)-like pathology but where the person showed no signs of cognitive impairment whilst they were alive.
UCLA researchers may have found a key to determining which Parkinson's disease patients will experience a more rapid decline in motor function, sparking hopes for the development of new therapies and helping identify those who could benefit most from early intervention.
Though there is no known cure for Parkinson’s disease, there are means to control the symptoms. Researchers at UCLA may have found a way to determine which patients will experience a more rapid decline in motor function, which is potentially beneficial in developing new therapies and identifying who can benefit the most from early intervention.
A new study led by Brown University researchers reports that percutaneous endoscopic gastric (PEG) feeding tubes, long assumed to help bedridden dementia patients stave off or overcome pressure ulcers, may instead make the horrible sores more likely to develop or not improve.
More Images (2 images) »